Cholesterol crystals and atherosclerotic plaque instability: therapeutic potential of eicosapentaenoic acid

Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT

Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction.

Role of omega-3 fatty acids in cardiovascular disease: the debate continues.

Role of omega-3 fatty acids in cardiovascular disease: the debate continues

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.

Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL

Is there a role for omega-3 fatty acids in cardiovascular disease risk reduction?